Inflammatory Disease

Biologic choices in plaque psoriasis hinge on access and adherence

<![CDATA[Experts Explore Individualized Treatment Strategies for Psoriasis]]>
jarmoluk / pixabay

By Amara Osei

Across 13 episodes of a case-based peer series, experts examined three plaque psoriasis cases and reached a consistent conclusion: biologic selection depends on access and adherence as much as efficacy. Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine, moderated the discussion with April Armstrong, MD, MPH, professor and chief of dermatology at UCLA.

The Dermatology Times Case-Based Peer Perspectives program was titled “Navigating Plaque Psoriasis Treatment: A Patient-Centered Approach to Therapy Selection.” It considered systemic eligibility, biologic efficacy and safety, comorbidity screening, dosing convenience, access barriers, and shared decision-making. A firsthand patient perspective supplied practical experience with access and long-term management; however, the series offered expert guidance without head-to-head efficacy or safety estimates.

When does plaque psoriasis warrant systemic therapy?

Armstrong cited International Psoriasis Council recommendations recognizing disease in high-impact areas—the scalp, nails, palms, soles, and genital region—and inadequate topical response as systemic-therapy criteria. Body surface area (BSA), the percentage of body surface affected, should not determine eligibility alone; functional burden, quality of life, and ability to maintain a regimen also matter.

How should clinicians select a first biologic?

The first case involved a 39-year-old roofing contractor with an 8-year history of plaque psoriasis affecting approximately 15% BSA. Sweating, sun exposure, and friction from occupational equipment worsened symptoms, while obesity, hypertension, and a family history of premature coronary artery disease complicated systemic treatment selection.

He had used topical corticosteroids inconsistently despite extensive disease involvement. Armstrong said extensive topical treatment can become impractical in physically demanding occupations, supporting consideration of systemic therapy for sustained disease control with a more manageable treatment burden. Before selecting that therapy, clinicians should screen for psoriatic arthritis, an inflammatory joint disease, and cardiometabolic conditions.

Armstrong framed biologic choice around three characteristics: “speed of onset, depth of response, and durability of efficacy.” She noted that contemporary biologics may provide both substantial skin clearance and sustained long-term responses, although the reported material did not quantify those benefits comparatively.

For a patient without previous systemic treatment, clinicians should consider those attributes alongside comorbidities such as obesity, diabetes, cardiovascular risk factors, or other inflammatory conditions. The case-based approach therefore evaluates the patient beyond skin outcomes rather than focusing exclusively on clearance.

What changes when psoriasis occurs in an older adult?

The second case involved a 72-year-old woman with late-onset plaque psoriasis affecting approximately 12% BSA. Her involvement was lower than the approximately 15% recorded in the first case, but itching disrupted walking and sleep, and hand osteoarthritis complicated topical application. She also had type 2 diabetes.

Her previous treatments included topical corticosteroids, roflumilast, and oral apremilast, but she frequently missed oral doses when her daily routine changed. The experts rejected advanced age alone as a reason to avoid biologics, favoring individualized safety assessment that accounts for comorbidities, concomitant medicines, medication burden, functional limitations, and overall health.

Biologics with extended dosing intervals and health care professional–administered injections may offer a lower treatment burden. Bunick said office-based administration can help patients with dexterity limitations or difficulty self-injecting, while Armstrong emphasized insurance coverage and Medicare reimbursement when evaluating treatment accessibility.

The experts cited real-world persistence data involving interleukin-23 (IL-23) inhibitors to emphasize that success depends on both clinical efficacy and continued use. Because the reported discussion gave no numerical persistence estimates, it does not permit a comparison of persistence across agents.

Is an inadequate response evidence that a biologic has failed?

The third case involved a 34-year-old hospital administrator working night shifts who struggled to maintain her biologic regimen. Her psoriasis affected high-impact sites, including the scalp and nails, making conventional BSA measurements an incomplete measure of disease burden.

Armstrong recommended distinguishing inadequate efficacy from poor adherence before changing therapy. Barriers to self-administered biologics included scheduling difficulties, injection technique, medication storage, and treatment-related anxiety. Possible responses included additional education, administration support, or a different dosing schedule.

The patient ultimately selected tildrakizumab, an IL-23 inhibitor administered every 12 weeks in a health care setting. The panel discussed site-specific efficacy data for tildrakizumab, secukinumab, and ustekinumab in scalp and nail psoriasis, without reporting comparative outcomes in the series summary. Long-term follow-up should track breakthrough symptoms, possible loss of response, treatment effectiveness, and adherence throughout care.

Can access determine whether an effective drug succeeds in practice?

Keki Mody, 83, described approximately three decades of psoriasis management and his progression from topical therapies to biologic treatment. His monoclonal gammopathy of undetermined significance, or MGUS, influenced his treatment journey, while insurance coverage and out-of-pocket expenses impeded access.

After discussing options with Bunick, Mody moved to tildrakizumab through Medicare Part B and reported meaningful improvement in disease control. The panel’s conclusion was explicit: clinicians must determine whether patients can “access, afford, and maintain treatment over time.”

Across the series, the experts assessed disease severity, comorbidities, treatment history, functional limitations, and patient preferences. They also placed systemic eligibility beyond BSA thresholds, weighed biologic efficacy and safety, and checked adherence before declaring treatment failure.

Two companion peer-perspective episodes were dated October 5 and October 19, 2026; they addressed first-line biologic selection in treatment-naive patients and access, adherence, and dosing frequency in older adults. The practical next step is to reassess disease control and adherence at each follow-up, while using extended intervals, administration support, and coverage discussions when continuity is threatened.

Source: dermatologytimes.com

Share this article:

Amara Osei

Show full bio

Correspondent covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Amara Osei →

Related articles

« Previous articleNext article »